Q4 2024 Stereotaxis Inc Earnings Call Transcript
Key Points
- Stereotaxis Inc (STXS) announced significant milestones with FDA submissions for key catheter innovations, indicating progress in their strategic transformation.
- The company reported a 39% year-over-year increase in fourth-quarter revenue, totaling $6.3 million, showcasing strong financial performance.
- Stereotaxis Inc (STXS) received European CE mark approval for the GenesisX robot and MAGiC ablation catheter, with plans for commercial launch in Europe.
- The strategic acquisition of APT has enhanced Stereotaxis Inc (STXS)'s in-house catheter development and manufacturing capabilities.
- The company is expanding its product portfolio with the introduction of the EMAGIN vascular catheter, targeting multiple new endovascular indications.
- Stereotaxis Inc (STXS) faces challenges with FDA regulatory approval timelines, particularly for the MAGiC catheter in the US.
- The company has a system backlog of $15.2 million, indicating potential delays in revenue recognition.
- Recurring revenue growth is impacted by catheter shortages from Johnson & Johnson, affecting overall financial performance.
- Operating expenses increased due to non-cash stock compensation and acquisition-related costs, impacting profitability.
- The macroeconomic environment and anti-corruption campaigns in China present headwinds for commercial efforts in the region.
Good morning. Thank you for joining us for Stereotaxis fourth-quarter and full-year 2024 earnings conference call. Certain statements during the conference call and question-and-answer period to follow may relate to future events, expectations, and as such, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the company in the future to be materially different from the statements that the company's executives may make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic report on Form 10-K or 10-Q. We assume no duty to update these statements.
(Operator Instructions) As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Stereotaxis.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
